Skip to Content
Merck
CN
  • Sterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patients.

Sterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patients.

The Journal of steroid biochemistry and molecular biology (2016-03-16)
William J Griffiths, Jonas Abdel-Khalik, Peter J Crick, Michael Ogundare, Cedric H Shackleton, Karin Tuschl, Mei Kwun Kwok, Brian W Bigger, Andrew A Morris, Akira Honda, Libin Xu, Ned A Porter, Ingemar Björkhem, Peter T Clayton, Yuqin Wang
ABSTRACT

Smith-Lemli-Opitz syndrome (SLOS) is a severe autosomal recessive disorder resulting from defects in the cholesterol synthesising enzyme 7-dehydrocholesterol reductase (Δ7-sterol reductase, DHCR7, EC 1.3.1.21) leading to a build-up of the cholesterol precursor 7-dehydrocholesterol (7-DHC) in tissues and blood plasma. Although the underling enzyme deficiency associated with SLOS is clear there are likely to be multiple mechanisms responsible for SLOS pathology. In an effort to learn more of the aetiology of SLOS we have analysed plasma from SLOS patients to search for metabolites derived from 7-DHC which may be responsible for some of the pathology. We have identified a novel hydroxy-8-dehydrocholesterol, which is either 24- or 25-hydroxy-8-dehydrocholesterol and also the known metabolites 26-hydroxy-8-dehydrocholesterol, 4-hydroxy-7-dehydrocholesterol, 3β,5α-dihydroxycholest-7-en-6-one and 7α,8α-epoxycholesterol. None of these metabolites are detected in control plasma at quantifiable levels (0.5ng/mL).

MATERIALS
Product Number
Brand
Product Description

Avanti
8(9)-dehydrocholesterol, Avanti Research - A Croda Brand